Format

Send to

Choose Destination
J Urol. 2004 Feb;171(2 Pt 2):S10-3; discussion S13-4.

Chemotherapeutic prevention studies of prostate cancer.

Author information

1
Department of Urology, Prostate Disease Center, Ludwig Boltzmand Institute for Prostatic disease, University of Vienna, Wahringer Gurtel 18-20, 1090, Austria. bdjavan@hotmail.com

Abstract

PURPOSE:

Despite advances in the detection and management of prostate cancer, this disease remains a major cause of morbidity and mortality in men. Increasing attention has focused on the role of chemoprevention for prostate cancer, ie the administration of agents that inhibit 1 or more steps in the natural history of prostate carcinogenesis. We review prostate cancer chemoprevention studies in Europe.

MATERIALS AND METHODS:

Published studies were identified in a search of MEDLINE. Information about ongoing studies was provided by author access to protocols.

RESULTS:

A variety of chemoprevention studies have focused on the role of dietary factors, vitamins and trace elements in prostate cancer. Some of these studies have been prospective, randomized and double-blinded, while others have used retrospective or epidemiological approaches. Large scale randomized studies are also evaluating the role of 5alpha-reductase inhibitors, which inhibit the conversion of testosterone to the more potent androgen dihydrotestosterone.

CONCLUSIONS:

Robust evidence is lacking for the value of chemopreventive agents in prostate cancer. Current evidence does suggest that vitamin E and selenium may have a role in prostate cancer chemoprevention. Data from 2 studies, 1 examining the type 1 5alpha-reductase selective inhibitor finasteride and the other using the dual 5alpha-reductase inhibitor dutasteride, will determine the benefits of androgen inhibition strategies for prostate cancer chemoprevention.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center